Assessment
olaparib
Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations (germline and/or somatic) progressing after prior therapy including a new hormonal agent (NHA)
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relations